热门资讯> 正文
AN 2 Therapeutics任命生物技术资深人士Cameron Trenor为CMO
2026-08-24 19:44
- AN2 Therapeutics (ANTX) appointed Cameron Trenor, M.D., as chief medical officer, bringing more than two decades of clinical and drug development experience.
- Trenor most recently served as chief medical officer at Cellarity, where he established the company's medical organization and led its lead program through its first IND submission and the start of a global first-in-human study.
- AN2 Therapeutics (ANTX) said Trenor will help advance its pipeline, which includes hematologic and infectious-disease programs, oncology candidates, and research programs targeting oncology, bone disorders, and infectious diseases.
More on AN2 Therapeutics
- AN2 rises after early-stage trial data for Chagas disease therapy
- Seeking Alpha’s Quant Rating on AN2 Therapeutics
- Historical earnings data for AN2 Therapeutics
- Financial information for AN2 Therapeutics
推荐文章
财报前瞻 |“超预期”已成标配？英伟达Q2营收、净利料翻倍，三大催化打破“利好兑现”魔咒？
美股前瞻 | 今晚凌晨两点！贝森特公布对伊”史诗级金融攻势“；拼多多绩后涨逾4%！此前一度跌近5%；存储、光通信盘前齐跌
一图看懂 | 拼多多Q2营收增约8%！经调整净利略超市场预期，研发投入同比大增40%
一图看懂 | 小鹏集团Q2毛利率20.7%超预期！旗下机器人子公司完成9亿美元融资，将正式布局人形机器人赛道
美股盘前 | 存储概念普跌，闪迪跌超4%；阿里巴巴跌超3.5%，宣布800亿港元港股配售；
阿里巴巴融资800亿股价大跌，市场热议港股“二次探底”
阿里重挫10%拖累恒科！港股史上最大配售落地，800亿港元全押AI遭“大空头”开炮，主权基金却逆势抢筹？
沃什若未提供明确指引 美国长债恐遭进一步抛售
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
